Daiwa Securities Group’s CytomX Therapeutics CTMX Stock Holding History

Daiwa Securities Group’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-564	Closed	-$2K	–	1248
2025 Q4	$2K	Buy	+564	New	+$2.14K	﹤0.01%	1301
2022 Q4	–	Sell	-102	Closed	–	–	1332
2022 Q3	$0	Hold	102	–	–	﹤0.01%	1350
2022 Q2	$0	Hold	102	–	–	﹤0.01%	1374
2022 Q1	$0	Hold	102	–	–	﹤0.01%	1385
2021 Q4	$0	Hold	102	–	–	﹤0.01%	1402
2021 Q3	$1K	Hold	102	–	–	﹤0.01%	1266
2021 Q2	$1K	Hold	102	–	–	﹤0.01%	1186
2021 Q1	$1K	Hold	102	–	–	﹤0.01%	1192
2020 Q4	$1K	Sell	102 -183	-64%	-$1.31K	﹤0.01%	1170
2020 Q3	$2K	Hold	285	–	–	﹤0.01%	1139
2020 Q2	$2K	Hold	285	–	–	﹤0.01%	1158
2020 Q1	$2K	Hold	285	–	–	﹤0.01%	1157
2019 Q4	$2K	Hold	285	–	–	﹤0.01%	1159
2019 Q3	$2K	Hold	285	–	–	﹤0.01%	1126
2019 Q2	$3K	Buy	285 +73	+34%	+$765	﹤0.01%	1127
2019 Q1	$2K	Hold	212	–	–	﹤0.01%	1128
2018 Q4	$3K	Hold	212	–	–	﹤0.01%	1090
2018 Q3	$4K	Hold	212	–	–	﹤0.01%	1091
2018 Q2	$5K	Hold	212	–	–	﹤0.01%	1094
2018 Q1	$6K	Buy	+212	New	+$6.05K	﹤0.01%	1061

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Daiwa Securities Group's CTMX Position: Q1 2026 in Review

Daiwa Securities Group sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 564 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in CTMX in Q1 2018 and held it in 20 quarters. The position peaked at $6K in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

Daiwa Securities Group reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
Daiwa Securities Group sold 564 CytomX Therapeutics shares in Q1 2026, an estimated $2K.
Daiwa Securities Group first reported a position in CytomX Therapeutics in Q1 2018 and held it in 20 quarters.
Daiwa Securities Group's CytomX Therapeutics position peaked at $6K in Q1 2018.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.